Skip to main content

FDA recall, , Moderate risk

American Health Packaging Cyanocobalamin Injection

Cyanocobalamin Injection may contain glass particles.

What happened

American Health Packaging is voluntarily recalling Cyanocobalamin Injection, USP, 1,000 mcg/mL, Rx Only, 25 x 1mL Multiple-Dose Vials per carton, manufactured by American Regent, Inc. for Bluepoint Laboratories, due to potential glass particle contamination. The recall was initiated on October 22, 2026, and added to the FDA's Enforcement Report on November 3, 2026. The product was distributed nationwide in the USA.

The issue was identified when American Regent, Inc. notified BluePoint Pharmaceuticals Laboratories about a foreign glass fragment in the product batch. Customers were notified by letter. The recall is voluntary and firm initiated, involving 4,097 cartons of the product.

What to do

The FDA notice gives no instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

Match the NDC and lot code listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. NDC
    • 68001-542-60
    • 68001-542-59
    Lot code
    • 24394A

Recall details

Posted by FDA
Recall began
Status
Open
Sold in

Nationwide in the USA

Recalled by
American Health PackagingColumbus, Ohio
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

FDA event number
100204
Recall number
D-0173-2027
Quantity recalled
4,097- cartons (25 x 1mL vials)
Recall type
Voluntary: Firm initiated
How the company first told customers
Letter

All recalls from American Health Packaging

Timeline

FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.

  1. American Health Packaging began the recall

  2. FDA posted the recall to its Enforcement Report

  3. Added to Recall Canary

  4. FDA rated the recall Class II (moderate risk)

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Nov 6, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)